The pharmaceutical landscape for Antibody-Drug Conjugates (ADCs) is led by several global powerhouses that dominate clinical pipelines, commercial approvals, and strategic partnerships. Key industry leaders include Daiichi Sankyo and AstraZeneca (renowned for their blockbuster DXd platform), Pfizer (following its massive acquisition of Seagen), AbbVie (incorporating ImmunoGen’s legacy tech), Roche / Genentech, Gilead Sciences, and Merck. These enterprises command the vast majority of approved oncology therapies, cutting-edge linker technologies, and multi-billion-dollar global development collaborations.